Insights from 2023 SABCS


 

SABCS 2023 Insights: "CAMBRIA 1 Study of Extended Adjuvant Therapy With Camizestrant vs. Standard ET in Patients With ER+/HER2- Early BC and an Intermediate/High Risk of Recurrence"

367 views
December 19, 2023
Comments 0
Login to view comments. Click here to Login